Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) has determined that the eleven drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to the drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Olivia Pritzlaff, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6308, Silver Spring, MD 20993-0002, 301-796-3601.End Further Info End Preamble Start Supplemental Information
In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products approved under an ANDA procedure. ANDA sponsors must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength andosage form as the “listed drug,” which is a version of the drug that was previously approved. Sponsors of ANDAs do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA). The only clinical data required in an ANDA are data to show that the drug that is the subject of the ANDA is bioequivalent to the listed drug.
The 1984 amendments include what is now section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(j)(7)), which requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the “Approved Drug Products With Therapeutic Equivalence Evaluations,” which is generally known as the “Orange Book.” Under FDA regulations, a drug is withdrawn from the list if the agency withdraws or suspends approval of the drug's NDA or ANDA for reasons of safety or effectiveness, or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162).
Under § 314.161(a) (21 CFR 314.161(a)), the agency must determine whether a listed drug was withdrawn from sale for reasons of safety or effectiveness: (1) Before an ANDA that refers to that listed drug may be approved; (2) whenever a listed drug is voluntarily withdrawn from sale and ANDAs that refer to the listed drug have been approved; and (3) when a person petitions for such a determination under 21 CFR 10.25(a) and 10.30. Section 314.161(d) provides that if FDA determines that a listed drug was withdrawn from sale for reasons of safety or effectiveness, the agency will initiate proceedings that could result in the withdrawal of approval of the ANDAs that refer to the listed drug.
FDA has become aware that the drug products listed in the table in this document are no longer being marketed. (As requested by the applicant, FDA withdrew approval of NDA 6-799 for RUBRAMIN PC (cyanocobalamin) Start Printed Page 77724Injection in the Federal Register of November 7, 2007 (72 FR 62858).)
|NDA 6-799||RUBRAMIN PC (cyanocobalamin) Injection, 1 milligram (mg)/milliliter (mL)||Bristol Myers Squibb Co., P.O. Box 4500, Princeton, NJ 08543-4500|
|NDA 10-060||FLORINEF (fludrocortisone acetate) Tablets, 0.1 mg||King Pharmaceuticals, Inc., 501 Fifth St., Bristol, TN 37620|
|NDA 11-613||IONAMIN (phentermine resin complex) Extended-Release Capsules, equivalent to (EQ) 15 mg and 30 mg base||UCB, Inc., 1950 Lake Park Dr., Smyrna, GA 30080|
|NDA 17-849||BRETHINE (terbutaline sulfate) Tablets, 2.5 mg and 5 mg||AAIPharma, LLC, 2320 Scientific Park Dr., Wilmington, NC 28405|
|NDA 17-970||NOLVADEX (tamoxifen citrate) Tablets, EQ 10 mg and 20 mg base||AstraZeneca Pharmaceuticals, 1800 Concord Pike, P.O. Box 8355, Wilmington, DE 19803-8355|
|NDA 19-058||TENORMIN (atenolol) Injection, 0.5 mg/mL||Do.|
|NDA 19-645||TORADOL (ketorolac tromethamine) Tablets, 10 mg||Hoffman-La Roche, Inc., 340 Kingsland St., Nutley, NJ 07110-1199|
|NDA 19-778||PRINZIDE (hydrochlorothiazide and lisinopril) Tablets, 25mg/20mg||Merck Research Laboratories, P.O. Box 1000, IG2C-50, North Wales, PA19454-1009|
|NDA 19-816||ORUVAIL (ketoprofen) Extended-Release Capsules, 100 mg, 150 mg, and 200 mg||Wyeth Pharmaceuticals, P.O. Box 8299, Philadelphia, PA 19101-8299|
|NDA 19-880||PARAPLATIN (carboplatin) for Injection, 50 mg/vial, 150 mg/vial, and 450 mg/vial||Bristol Myers Squibb Co.|
|NDA 50-582||DORYX (doxycycline hyclate) Delayed-Release Capsules, EQ 75 mg and 100 mg base||F.H. Faulding and Co., c/o Warner Chilcott, Inc., Rockaway 80 Corporate Center, 100 Enterprise Dr., suite 280, Rockaway, NJ 07866|
FDA has reviewed its records and, under § 314.161, has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. Accordingly, the agency will continue to list the drug products listed in this document in the “Discontinued Drug Product List” section of the Orange Book. The “Discontinued Drug Product List” identifies, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness.
Approved ANDAs that refer to the NDAs listed in this document are unaffected by the discontinued marketing of the products subject to those NDAs. Additional ANDAs that refer to these products may also be approved by the agency if they comply with relevant legal and regulatory requirements. If FDA determines that labeling for these drug products should be revised to meet current standards, the agency will advise ANDA applicants to submit such labeling.Start Signature
Dated: December 11, 2008.
Associate Commissioner for Policy and Planning.
[FR Doc. E8-30154 Filed 12-18-08; 8:45 am]
BILLING CODE 4160-01-S